AllSci News
CHMP backs tumor-agnostic EU use of Enhertu across HER2-positive solid tumors
Daiichi Sankyo and AstraZeneca's Enhertu receives CHMP recommendation for HER2-positive solid tumors in the EU
Inovio's VGX-3100 meets primary endpoint in Phase III cervical dysplasia trial in China
ApolloBio, Inovio Pharmaceuticals' (Nasdaq: INO) Chinese partner, has announced that VGX-3100, a DNA immunotherapy targeting HPV16 and HPV18, met its...
Swedish Orphan Biovitrum's pozdeutinurad meets primary endpoint in Phase III gout trial
Swedish Orphan Biovitrum (STO: SOBI) reported that both doses of pozdeutinurad met the primary endpoint in the Phase III REDUCE 2 study, with 69.2% of...
Biogen and Denali's pull plug on LRRK2 inhibitor after Phase II failure in early Parkinson's
Biogen (Nasdaq: BIIB) and Denali Therapeutics (Nasdaq: DNLI) reported that BIIB122 (DNL151), a selective small-molecule LRRK2 inhibitor, failed to slow...
Boehringer Ingelheim's Hernexeos receives conditional approval in China for HER2-mutant advanced NSCLC
Boehringer Ingelheim has received conditional approval from China's National Medical Products Administration (NMPA) for zongertinib (Hernexeos) as a...
Ingenia Therapeutics gains Korea Exchange approval for public listing amid Merck partnership
Ingenia Therapeutics, a Watertown, Massachusetts-based biotechnology company whose lead ophthalmology antibody is being developed by Merck, received...
ASCO: 858 Therapeutics' posts 57% response rate for PARG inhibitor in BRCA-mutated ovarian and breast cancer
858 Therapeutics reported a 57% objective response rate for ETX-19477 in a small Phase 2-eligible subset of patients with BRCA-mutated platinum-resistant...
Whitehawk Therapeutics licenses Hangzhou DAC's CPT113 linker-payload for up to five ADC programs
Whitehawk Therapeutics (Nasdaq: WHWK) has entered an option agreement with China's Hangzhou DAC Biotech to access the CPT113 linker-payload technology...
ASCO: Innovent, Takeda's PD-1/IL-2 bispecific shows 86.4% response rate in early trial for NSCLC
Innovent Biologics (HKEX: 01801), the Suzhou-based biopharmaceutical company, reported preliminary proof-of-concept data from the IBI363 NSCLC trial at the...
Oorja Bio emerges from stealth mode with USD 30m Series A to advance pulmonary fibrosis peptide ORJ-001
Oorja Bio, a Houston-based clinical-stage biopharmaceutical company, has launched with USD 30 million in Series A financing from founding investor Westlake...
MaaT Pharma receives negative trend opinion from European Medicines Agency for Xervyteg
MaaT Pharma (Euronext: MAAT), based in Lyon, France, received a “negative trend” opinion from the European Medicines Agency’s Committee for Medicinal Products…
Bayer’s finerenone mineralocorticoid receptor antagonist gains FDA Priority Review for type 1 diabetes
Bayer announced receipt of US FDA Priority Review status for its supplemental New Drug Application (sNDA) relating to Kerendia (finerenone), a non-steroidal…
Scribe's epigenetic silencer targeting PCSK9 for single-dose LDL reduction enters first human trial
Scribe Therapeutics, an Alameda, California-based biotechnology company, has received clearance from the Australian Therapeutic Goods Administration (TGA)...
Lupeng's rocbrutinib challenges Eli Lilly's Jaypirca in Phase III relapsed refractory CLL trial
Lupeng Pharmaceutical Ltd has enrolled the first patient in the ROCKET-CLL trial, a global Phase III study pitting rocbrutinib (LP-168) directly against Eli...
BioMarin's vosoritide meets primary endpoint in Phase III hypochondroplasia trial
BioMarin Pharmaceutical (Nasdaq: BMRN) reported that vosoritide (Voxzogo) met its primary endpoint in the Phase III CANOPY-HCH-3 study in children with...
The AllSci Brief
Systematic R&D and deal news. Daily.